Novacyt: Yourgene shareholders approve the buyout
In a statement issued yesterday, Yourgene said that almost 98.9% of the voting rights cast were in favor of the transaction.
Early last month, Novacyt announced its intention to make a friendly offer to acquire Yourgene for £16.7 million (around €19.5 million).
The group had justified the operation by its desire to establish a "post-Covid" strategy and become a "broader" and "diversified" player in the diagnostics business.
Based in Manchester, Yourgene offers DNA microbiology tools, in particular non-invasive prenatal screening (NIPT) devices, notably for Down syndrome (trisomy 21).
Listed on the Paris Bourse, Novacyt's share price rose by over 2% on Friday morning following this announcement.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction